Breast cancer in men in the United States
Open Access
- 20 July 2010
- Vol. 116 (15), 3558-3568
- https://doi.org/10.1002/cncr.25153
Abstract
BACKGROUND: Breast cancer in men is rare, so clinical trials are not practical. Recommendations suggest treating men who are diagnosed with breast cancer using the guidelines for postmenopausal women; however, to date, no population‐based studies have evaluated patterns of care. METHODS: To examine characteristics, treatment, and survival among men with newly diagnosed breast cancer, in 2003 and 2004, 512 men were identified from the Surveillance, Epidemiology and End Results Program. Data were reabstracted and therapy was verified through the patients' treating physicians. RESULTS: The majority of men (79%) were diagnosed through discovery of a breast lump or other signs/symptoms. Among men who had invasive disease, 86% underwent mastectomy, 37% received chemotherapy, and 58% received hormone therapy. In multivariate analysis, tumor size (P = .01) and positive lymph node status (P < .0001) were associated positively with the use of chemotherapy, whereas age group (P < .0001) and current unmarried status (P = .01) had negative associations. Among men who had invasive, estrogen receptor (ER)‐positive/borderline tumors, the use of tamoxifen or aromatase inhibitors (AIs) was associated with age group (P = .05). Among men who had invasive disease, cancer mortality was associated with tumor size (P < .0001). Among men with ER‐positive/borderline disease, increased cancer mortality was associated with tumor size (P < .0001), current unmarried status (P = .04), and decreased mortality with tamoxifen (P = .04). CONCLUSIONS: Tumor characteristics and marital status were the primary predictors of therapy and cancer mortality among men with breast cancer. Although AIs are not currently recommended, they are commonly prescribed. However, their use did not result in a decrease in cancer mortality. Research must examine the efficacy of AIs with and without gonadotropin‐releasing hormone analogues. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- Is mode of breast cancer detection associated with cancer treatment in the United States?Cancer, 2008
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Comparative Analysis of Sentinel Lymph Node Operation in Male and Female Breast Cancer PatientsJournal of the American College of Surgeons, 2006
- Leuprolide Acetate Plus Aromatase Inhibition for Male Breast CancerJournal of Clinical Oncology, 2006
- Comparative Epidemiology of Breast Cancer Among Men and Women in the US, 1996 to 2000Cancer Causes & Control, 2006
- Breast carcinoma in menCancer, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerThe New England Journal of Medicine, 2004
- Is Male Breast Cancer Similar or Different than Female Breast Cancer?Breast Cancer Research and Treatment, 2004
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987